HRP20201736T1 - Postupak liječenja diskinezije - Google Patents
Postupak liječenja diskinezije Download PDFInfo
- Publication number
- HRP20201736T1 HRP20201736T1 HRP20201736TT HRP20201736T HRP20201736T1 HR P20201736 T1 HRP20201736 T1 HR P20201736T1 HR P20201736T T HRP20201736T T HR P20201736TT HR P20201736 T HRP20201736 T HR P20201736T HR P20201736 T1 HRP20201736 T1 HR P20201736T1
- Authority
- HR
- Croatia
- Prior art keywords
- opioid receptor
- kappa
- receptor antagonist
- receptor agonist
- nalbuphine
- Prior art date
Links
- 208000012661 Dyskinesia Diseases 0.000 title claims 2
- 239000002632 kappa opiate receptor agonist Substances 0.000 claims 15
- 239000002623 mu opiate receptor antagonist Substances 0.000 claims 15
- 229940126470 kappa opioid receptor agonist Drugs 0.000 claims 14
- 230000009977 dual effect Effects 0.000 claims 11
- 229940002612 prodrug Drugs 0.000 claims 10
- 239000000651 prodrug Substances 0.000 claims 10
- 229960000805 nalbuphine Drugs 0.000 claims 9
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 8
- 229940125688 antiparkinson agent Drugs 0.000 claims 7
- 239000000939 antiparkinson agent Substances 0.000 claims 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 3
- 239000000443 aerosol Substances 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- -1 Nalbuphine benzoate ester Chemical class 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000007933 dermal patch Substances 0.000 claims 1
- 150000005690 diesters Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Claims (13)
1. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora ili njegov predlijek za uporabu u liječenju ili ublažavanju diskinezije izazvane levodopom kod subjekta kojem je dijagnosticirana Parkinsonova bolest; pri čemu antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora sadrži Nalbufin, primijenjen u dozi između 0.001 mg / kg i 3 mg / kg; i
pri čemu je navedeni predlijek odabran iz skupine koja se sastoji od benzoatnog estera Nalbufina, sebakoilnog diestra Nalbufina, pegiliranih derivata Nalbufina i njihovih farmaceutski prihvatljivih soli.
2. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora prema zahtjevu 1, za uporabu prema zahtjevu 1, koji sadrži Nalbufin u neinjekcijskom pripravku koji sadrži:
a. aktivnu komponentu koja uključuje Nalbufin u obliku slobodne baze ili soli, u količini od najmanje 0.01 mg; i
b. farmaceutski prihvatljiv nosač;
pri čemu je navedeni sastav u obliku tablete ili kapsule.
3. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora prema zahtjevu 1, za uporabu prema zahtjevu 1, naznačen time što sadrži Nalbufin u neinjekcijskom farmaceutskom pripravku, pri čemu je navedeni farmaceutski pripravak u obliku odabranom iz skupine koja se sastoji od tableta, kapsula, sirupa, gelova, supozitorija, flastera za kožu, inhalacijskih prašaka, inhalacijskih aerosola, sublingvalnih sprejeva, sublingvalnih čvrstih oblika doziranja, intranazalnih sprejeva i intranazalnih aerosoli, ili putem medicinskog uređaja sposobnog za kontinuiranu isporuku farmaceutskog sredstva.
4. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora ili njegov predlijek prema bilo kojem od zahtjeva 1 do 3, za uporabu prema bilo kojem od zahtjeva 1 do 3, primijenjen s drugim anti-Parkinsonovim sredstvom odabranim od skupine koja se sastoji od L-DOPA, agonista dopamina, MAO inhibitora, COMT inhibitora, amantadina i anti-kolinergika.
5. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora ili njegov predlijek prema zahtjevu 4, za uporabu prema zahtjevu 4, naznačen time što je navedeno drugo anti-Parkinsonovo sredstvo L-DOPA.
6. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora ili njegov predlijek prema zahtjevu 4, za uporabu prema zahtjevu 4, naznačen time što je navedeno drugo anti-Parkinsonovo sredstvo agonist dopamina.
7. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora ili njegov predlijek prema zahtjevu 4, za uporabu prema zahtjevu 4, naznačen time što je navedeno drugo anti-Parkinsonovo sredstvo MAO inhibitor.
8. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora ili njegov predlijek prema zahtjevu 4, za uporabu prema zahtjevu 4, naznačen time što je navedeno drugo anti-Parkinsonovo sredstvo COMT inhibitor.
9. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora ili njegov predlijek prema zahtjevu 4, za uporabu prema zahtjevu 4, naznačen time što je navedeno drugo anti-Parkinsonovo sredstvo amantadin.
10. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora ili njegov predlijek prema zahtjevu 4, za uporabu prema zahtjevu 4, naznačen time što je navedeno drugo anti-Parkinsonovo sredstvo anti-kolinergik.
11. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora ili njegov predlijek prema bilo kojem od zahtjeva 4 do 10, za uporabu u prema bilo kojem od zahtjeva 4 do 10, naznačen time što se primjena bilo kojeg od sredstava odgađa 0-12 sati, i primjena je istim ili drugim putem.
12. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora prema zahtjevu 1, za uporabu prema zahtjevu 1, naznačeni time što navedeni mu-antagonist dvostrukog djelovanja / kappa-agonist sadrži Nalbufin primijenjen kontinuiranom infuzijom.
13. Antagonist mu-opioidnog receptora dvostrukog djelovanja / agonist kappa-opioidnog receptora prema zahtjevu 2 ili zahtjevu 3, za uporabu prema zahtjevu 2 ili zahtjevu 3, naznačen time što se Nalbufin primjenjuje oralno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480415P | 2011-04-29 | 2011-04-29 | |
| PCT/US2012/035129 WO2012149113A1 (en) | 2011-04-29 | 2012-04-26 | Method of treating dyskinesia |
| EP12777826.4A EP2701707B1 (en) | 2011-04-29 | 2012-04-26 | Method of treating dyskinesia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201736T1 true HRP20201736T1 (hr) | 2021-03-19 |
Family
ID=47072743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201736TT HRP20201736T1 (hr) | 2011-04-29 | 2020-10-28 | Postupak liječenja diskinezije |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9289423B2 (hr) |
| EP (1) | EP2701707B1 (hr) |
| CA (1) | CA2834735C (hr) |
| CY (1) | CY1123614T1 (hr) |
| DK (1) | DK2701707T3 (hr) |
| ES (1) | ES2829223T3 (hr) |
| HR (1) | HRP20201736T1 (hr) |
| HU (1) | HUE052542T2 (hr) |
| LT (1) | LT2701707T (hr) |
| PL (1) | PL2701707T3 (hr) |
| PT (1) | PT2701707T (hr) |
| SI (1) | SI2701707T1 (hr) |
| WO (1) | WO2012149113A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071088B2 (en) | 2012-06-26 | 2018-09-11 | Precondit, Llc | Anti-nausea drug combinations |
| US20150352099A1 (en) * | 2014-06-04 | 2015-12-10 | Mentinova Inc. | Compositions and Methods of Reducing Sedation |
| WO2016029218A1 (en) | 2014-08-22 | 2016-02-25 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation |
| WO2017173067A1 (en) * | 2016-03-31 | 2017-10-05 | Versi Group, Llc | Delta opioid agonist, mu opioid antagonist compositions and methods for treating parkinson's disease |
| JP6865235B2 (ja) * | 2016-12-28 | 2021-04-28 | 久光製薬株式会社 | ブトルファノール含有貼付剤 |
| US11186585B2 (en) | 2018-08-17 | 2021-11-30 | Kappa-Pharma LLC | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
| WO2021142288A1 (en) * | 2020-01-10 | 2021-07-15 | Trevi Therapeutics, Inc. | Methods of administering nalbuphine |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0615756B1 (en) | 1993-03-15 | 2001-06-27 | National Science Council | Nalbuphine esters and long-acting pharmaceutical compositions containing them |
| CN1049577C (zh) | 1994-02-28 | 2000-02-23 | 胡幼圃 | 那布扶林镇痛剂的长效前体药物及其制备方法 |
| US5750534A (en) | 1994-03-16 | 1998-05-12 | National Science Council | Nalbuphine esters having long acting analgesic action and method of use |
| AUPO274596A0 (en) * | 1996-10-04 | 1996-10-31 | Armstrong, Stuart Maxwell | Method for the treatment of neurological or neuropsychiatric disorders |
| EP1149836B1 (en) | 2000-04-27 | 2003-02-26 | Oliver Yoa-Pu Hu | Polynalbuphine derivatives |
| AU2001268353A1 (en) * | 2000-06-09 | 2001-12-17 | The Regents Of The University Of California | Method of treating pain using nalbuphine and opioid antagonists |
| WO2002009768A2 (en) | 2000-07-27 | 2002-02-07 | Rutgers, The State University | Therapeutic polyesters and polyamides |
| US6569449B1 (en) | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
| US6703398B2 (en) * | 2001-11-26 | 2004-03-09 | Oliver Yoa-Pu Hu | Orally administered analgesic compositions containing nalbuphine |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| WO2005009377A2 (en) | 2003-07-23 | 2005-02-03 | University Of Kentucky Research Foundation | Novel oral bioavailable prodrugs |
| US20050137141A1 (en) | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
| US8163701B2 (en) | 2005-08-19 | 2012-04-24 | Signature Therapeutics, Inc. | Prodrugs of active agents |
| US8394812B2 (en) | 2005-08-24 | 2013-03-12 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
| WO2007025005A2 (en) | 2005-08-24 | 2007-03-01 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
| WO2007127683A2 (en) | 2006-04-25 | 2007-11-08 | Michael Victor Voronkov | Administration of agonist-antagonist in opioid-dependent patients |
| US20090186832A1 (en) | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid peptide pro-drugs of phenolic analgesics and uses thereof |
| JP2013523599A (ja) | 2009-04-02 | 2013-06-17 | シャイア エルエルシー | 新規なオピオイドのジカルボン酸結合アミノ酸及びペプチドプロドラッグ並びにその用途 |
| BR112012001164A2 (pt) | 2009-07-17 | 2016-03-01 | Shire Llc | aminoácido de carbamato e pró-fármacos de peptídeo de opioides e usos dos mesmos |
| WO2011083304A1 (en) | 2010-01-05 | 2011-07-14 | Shire Llc | Prodrugs of opioids and uses thereof |
| TW201628618A (zh) * | 2010-12-28 | 2016-08-16 | 歐 賽提克股份有限公司 | 用於治療巴金森氏症的類鴉片激動劑與類鴉片拮抗劑之組合 |
-
2012
- 2012-04-26 SI SI201231848T patent/SI2701707T1/sl unknown
- 2012-04-26 HU HUE12777826A patent/HUE052542T2/hu unknown
- 2012-04-26 ES ES12777826T patent/ES2829223T3/es active Active
- 2012-04-26 PT PT127778264T patent/PT2701707T/pt unknown
- 2012-04-26 EP EP12777826.4A patent/EP2701707B1/en active Active
- 2012-04-26 LT LTEP12777826.4T patent/LT2701707T/lt unknown
- 2012-04-26 PL PL12777826T patent/PL2701707T3/pl unknown
- 2012-04-26 DK DK12777826.4T patent/DK2701707T3/da active
- 2012-04-26 US US14/113,340 patent/US9289423B2/en active Active
- 2012-04-26 CA CA2834735A patent/CA2834735C/en active Active
- 2012-04-26 WO PCT/US2012/035129 patent/WO2012149113A1/en active Application Filing
-
2020
- 2020-10-20 CY CY20201100989T patent/CY1123614T1/el unknown
- 2020-10-28 HR HRP20201736TT patent/HRP20201736T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2834735A1 (en) | 2012-11-01 |
| LT2701707T (lt) | 2021-01-25 |
| JP2014523404A (ja) | 2014-09-11 |
| WO2012149113A1 (en) | 2012-11-01 |
| PL2701707T3 (pl) | 2021-03-08 |
| US9289423B2 (en) | 2016-03-22 |
| ES2829223T3 (es) | 2021-05-31 |
| EP2701707B1 (en) | 2020-09-02 |
| EP2701707A4 (en) | 2014-11-19 |
| EP2701707A1 (en) | 2014-03-05 |
| JP6134703B2 (ja) | 2017-05-24 |
| US20140221415A1 (en) | 2014-08-07 |
| CA2834735C (en) | 2021-06-01 |
| CY1123614T1 (el) | 2022-03-24 |
| HUE052542T2 (hu) | 2021-05-28 |
| DK2701707T3 (da) | 2020-11-02 |
| SI2701707T1 (sl) | 2021-02-26 |
| PT2701707T (pt) | 2020-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201736T1 (hr) | Postupak liječenja diskinezije | |
| HRP20200600T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| HRP20160327T1 (hr) | Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| PH12016501342A1 (en) | Intranasal pharmaceutical dosage forms comprising naloxone | |
| HK1200742A1 (en) | Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and or aversive agent, polyalkylene oxide and anionic polymer | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| RS53995B1 (en) | NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF OPIOID SUBSTANCE | |
| PL2398468T3 (pl) | Kompozycje farmaceutyczne zawierające zasadę prasugrelu lub jej farmaceutycznie dopuszczalne kwasowe sole addycyjne i sposoby ich otrzymywania | |
| WO2012054831A3 (en) | Ready to use ketorolac formulations | |
| MX2011011028A (es) | Agonista del receptor beta de hormona tiroidea novedoso. | |
| MX2013001757A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| IL217052A0 (en) | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them | |
| RU2013136350A (ru) | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист | |
| JP2015523407A5 (hr) | ||
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| PH12014501408A1 (en) | Immediate release multi unit pellet system | |
| RU2014115287A (ru) | Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения | |
| EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
| EA200901146A1 (ru) | Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли | |
| WO2012063005A3 (fr) | Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation | |
| HRP20171930T1 (hr) | Analozi diazonamida | |
| JP2014523404A5 (hr) | ||
| MX2014005960A (es) | Compuestos de anillo fusionado que contienen nitrogeno como antagonistas crth2. |